We use Google Analytics to count anonymous page views and understand which content gets read. No ads, no profiles. Decline keeps you on cookieless mode. Details.
Gilead Sciences, Inc.
Health Care · Biotechnology
$GILD is an HIV-cash-cow funding an oncology pivot. Biktarvy (~$13B/yr, >50% U.S. HIV treatment share) is the structural anchor; lenacapavir (twice-yearly injectable PrEP, Sunlenca/Yeztugo) extends the HIV moat into 2030s and re-rates the franchise.
- Biktarvy + Descovy run-rate gives durable ~$18B HIV revenue base, patent runway protected by lenacapavir long-acting follow-on
- Lenacapavir PrEP PURPOSE-1/2 readouts: 100% / 99.9% efficacy - best-in-class data, potential category expansion vs $TGTX, ViiV
- Trodelvy expanding label (TNBC + urothelial, HR+/HER2- pending) - first real non-HIV growth leg in years
- CAR-T (Yescarta/Tecartus) ~$1.5B run-rate, gross-margin accretive vs HCV decay
- Capital return: ~3.5% dividend yield + active buyback, ~12-13x fwd P/E vs $MRK $BMY $PFE peer median
- HCV (Epclusa/Vosevi) revenue continues structural decay (~$1.5B and falling) - no replacement leg
- Veklury cliff: COVID antiviral demand collapsing, ~$2B headwind into 2026/27
- Oncology pivot still unproven at scale - Trodelvy growth decelerating, CAR-T competitive (BMY, $NVS Kymriah, Carvykti)
- Lenacapavir PrEP commercial ramp depends on payer access + Descovy cannibalization
- Biktarvy LOE 2033 - no clear post-Biktarvy HIV regimen at scale yet
Each weekday: the scan's ENTER setups with entry, stop and target, every new ticker teardown, and the bubble shifts that move names like this one. Free. Education, not advice.
No spam. One email per day max. Pro adds Telegram trade alerts and higher AI-assistant limits.
Auto-computed retracement of the trailing 52w low-high leg. Recomputed on each refresh; not a curated level.
Auto-computed retracement of the trailing 52w low-high leg. Recomputed on each refresh; not a curated level.